Relationship between age and chemotherapy regimen for elderly patients with advanced lung cancer
Conclusions: Renal dysfunction was significantly more common in elderly patients with non-Sq NSCLC. A relationship between age and regimen was observed in these patients. (Source: European Respiratory Journal)
Source: European Respiratory Journal - October 27, 2023 Category: Respiratory Medicine Authors: Shiiba, R., Kogure, Y., Murao, H., Takigawa, Y., Torii, A., Yamada, A., Shinohara, Y., Niwa, H., Sano, M., Kitagawa, C., Oki, M. Tags: Lung cancer Source Type: research
Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: Primary results from the phase 3 MARIPOSA-2 study
CONCLUSIONS: Amivantamab-chemotherapy and amivantamab-lazertinib-chemotherapy improved progression-free survival and intracranial progression-free survival versus chemotherapy in a population with limited options after disease progression on osimertinib. Longer follow-up is needed for the modified amivantamab-lazertinib-chemotherapy regimen.PMID:37879444 | DOI:10.1016/j.annonc.2023.10.117 (Source: Ann Oncol)
Source: Ann Oncol - October 25, 2023 Category: Cancer & Oncology Authors: A Passaro Jie Wang Y Wang S-H Lee B Melosky J-Y Shih Jialei Wang K Azuma O Juan-Vidal M Cobo E Felip N Girard A B Cortot R Califano F Cappuzzo S Owen S Popat J-L Tan J Salinas P Tomasini R D Gentzler W N William K L Reckamp T Takahashi S Ganguly D M Kowal Source Type: research
Amivantamab plus Chemotherapy in NSCLC with < em > EGFR < /em > Exon 20 Insertions
CONCLUSIONS: The use of amivantamab-chemotherapy resulted in superior efficacy as compared with chemotherapy alone as first-line treatment of patients with advanced NSCLC with EGFR exon 20 insertions. (Funded by Janssen Research and Development; PAPILLON ClinicalTrials.gov number, NCT04538664.).PMID:37870976 | DOI:10.1056/NEJMoa2306441 (Source: Cell Research)
Source: Cell Research - October 23, 2023 Category: Cytology Authors: Caicun Zhou Ke-Jing Tang Byoung Chul Cho Baogang Liu Luis Paz-Ares Susanna Cheng Satoru Kitazono Muthukkumaran Thiagarajan Jonathan W Goldman Joshua K Sabari Rachel E Sanborn Aaron S Mansfield Jen-Yu Hung Michael Boyer Sanjay Popat Josiane Mour ão Dias E Source Type: research
A Phase 3, Randomized study of atezolizumab plus bevacizumab and chemotherapy in patients with EGFR or ALK mutated in non-small cell lung cancer (ATTLAS, KCSG-LU19-04)
CONCLUSION: This study is the first randomized phase 3 study to demonstrate the clinical benefit of anti-PD-L1 antibody in combination with bevacizumab and chemotherapy in EGFR or ALK mutated NSCLC who have progressed on relevant targeted therapy.PMID:37861993 | DOI:10.1200/JCO.23.01891 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - October 20, 2023 Category: Cancer & Oncology Authors: Sehhoon Park Tae Min Kim Ji-Youn Han Gyeong-Won Lee Byoung Yong Shim Yun-Gyoo Lee Sang-We Kim Il Hwan Kim Suee Lee Yu Jung Kim Ji Hyun Park Sang-Gon Park Ki Hyeong Lee Eun Joo Kang Ju Won Kim Seong-Hoon Shin Chan-Young Ock Byung-Ho Nam Jaebong Lee Hyun-Ae Source Type: research
A Phase 3, Randomized study of atezolizumab plus bevacizumab and chemotherapy in patients with EGFR or ALK mutated in non-small cell lung cancer (ATTLAS, KCSG-LU19-04)
CONCLUSION: This study is the first randomized phase 3 study to demonstrate the clinical benefit of anti-PD-L1 antibody in combination with bevacizumab and chemotherapy in EGFR or ALK mutated NSCLC who have progressed on relevant targeted therapy.PMID:37861993 | DOI:10.1200/JCO.23.01891 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - October 20, 2023 Category: Cancer & Oncology Authors: Sehhoon Park Tae Min Kim Ji-Youn Han Gyeong-Won Lee Byoung Yong Shim Yun-Gyoo Lee Sang-We Kim Il Hwan Kim Suee Lee Yu Jung Kim Ji Hyun Park Sang-Gon Park Ki Hyeong Lee Eun Joo Kang Ju Won Kim Seong-Hoon Shin Chan-Young Ock Byung-Ho Nam Jaebong Lee Hyun-Ae Source Type: research
Toxic Epidermal Necrolysis Induced by Sintilimab: A Case Report
We describe a case of toxic epidermal necrolysis related to sintilimab in an elderly oncologic patient. 3 weeks after immunotherapy, the patient developed an extensive rash and diffuse itching, rapidly evolving into macules, blisters, bullae and erosions. Causal evaluation was performed based on the algorithm of drug causality for epidermal necrolysis and national Food and Drug Administration qualitative analysis. The patient responded to high-dose glucocorticosteroid and supportive therapy, alongside with local wound care. If immune checkpoint inhibitors need to be extrapolated clinically, strictly following evidence-base...
Source: Annals of Dermatology - October 19, 2023 Category: Dermatology Authors: Ya-Lei Lye Bin Shan Chen-Hong Jia Jiang Liu Juan Hou Wen-Li Du Rui Feng Ping Liang Source Type: research
Toxic Epidermal Necrolysis Induced by Sintilimab: A Case Report
We describe a case of toxic epidermal necrolysis related to sintilimab in an elderly oncologic patient. 3 weeks after immunotherapy, the patient developed an extensive rash and diffuse itching, rapidly evolving into macules, blisters, bullae and erosions. Causal evaluation was performed based on the algorithm of drug causality for epidermal necrolysis and national Food and Drug Administration qualitative analysis. The patient responded to high-dose glucocorticosteroid and supportive therapy, alongside with local wound care. If immune checkpoint inhibitors need to be extrapolated clinically, strictly following evidence-base...
Source: Annals of Dermatology - October 19, 2023 Category: Dermatology Authors: Ya-Lei Lye Bin Shan Chen-Hong Jia Jiang Liu Juan Hou Wen-Li Du Rui Feng Ping Liang Source Type: research
